Zacks: MediciNova, Inc. (NASDAQ:MNOV) Given $20.67 Consensus Price Target by Brokerages
Shares of MediciNova, Inc. (NASDAQ:MNOV) have received an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus target price of $20.67 for the company and are expecting that the company will post ($0.15) earnings per share for the current quarter, according to Zacks. Zacks has also assigned MediciNova an industry rank of 100 out of 256 based on the ratings given to its competitors.
Separately, BidaskClub downgraded MediciNova from a “sell” rating to a “strong sell” rating in a report on Friday, August 16th.
NASDAQ MNOV traded up $0.31 on Wednesday, hitting $9.15. The company’s stock had a trading volume of 108,700 shares, compared to its average volume of 100,099. MediciNova has a 1-year low of $6.68 and a 1-year high of $13.37. The company’s 50-day moving average is $9.28 and its 200 day moving average is $9.61. The firm has a market cap of $391.97 million, a PE ratio of -25.42 and a beta of 1.19.
MediciNova Company Profile
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.
Featured Story: What is quantitative easing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.